TEE
TCRT icon

Tibra Equities Europe’s Alaunos Therapeutics TCRT Stock Holding History

Tibra Equities Europe’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-315
Closed -$202K – 298
2019
Q3 		$202K Buy
+315
New +$250K 0.02% 210

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tibra Equities Europe's TCRT Position: Q4 2019 in Review

Tibra Equities Europe sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 315 shares — an estimated $202K sold.

Tibra Equities Europe first reported a position in TCRT in Q3 2019 and held it in 1 quarter. The position peaked at $202K in Q3 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • Tibra Equities Europe reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 315 Alaunos Therapeutics shares in Q4 2019, an estimated $202K.
  • Tibra Equities Europe first reported a position in Alaunos Therapeutics in Q3 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Alaunos Therapeutics position peaked at $202K in Q3 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on Tibra Equities Europe's 13F filing for Q4 2019, filed 14 Feb 2020.